ada standards of care 2025 glp-1 receptor agonists recommendations Diabetes (2025) - Guidelines Spotlight GLP-1 Receptor Agonist Market Size
Description
Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88
If you are taking medications or have a medical condition, speak with your provider before use
To overcome this limitation, various modifications and delivery strategies to enhance the pharmacokinetic properties and therapeutic efficacy of GLP-1 analogs have been studied
Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.
